Carisma Therapeutics Inc. (CARM) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CARM currently has 41.8M outstanding shares. with significant dilution risk as 127M authorized shares could dilute existing holders by 304.2%. The company has minimally diluted shareholders by 1.3% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Dec 15, 2025 |
POS AM filing: Registration Statement on Form S-3 registering the offering, issuance and sale by the Registrant of up to $300,000,000 of the Registrant's debt securities, Common Stock, preferred stock, depositary shares, subscription rights, warrants to purchase Common Stock, preferred stock, depositary shares or debt securities, and units. |
42M | 130M |
| Dec 15, 2025 |
POS AM filing: Registration Statement on Form S-3 registering the offering, issuance and sale by the Registrant of up to $300,000,000 of the Registrant's debt securities, Common Stock, preferred stock, depositary shares, subscription rights, warrants to purchase Common Stock, preferred stock, depositary shares or debt securities, and units. |
42M | 130M |
| Dec 15, 2025 |
POS AM filing: Registration Statement on Form S-3 registering the offering, issuance and sale by the Registrant of up to $300,000,000 of the Registrant's debt securities, Common Stock, preferred stock, depositary shares, subscription rights, warrants to purchase Common Stock, preferred stock, depositary shares or debt securities, and units. |
42M | 130M |
| Dec 15, 2025 |
POS AM filing: Registration Statement on Form S-3 registering the offering, issuance and sale by the Registrant of up to $300,000,000 of the Registrant's debt securities, Common Stock, preferred stock, depositary shares, subscription rights, warrants to purchase Common Stock, preferred stock, depositary shares or debt securities, and units. |
42M | 130M |
| Nov 12, 2025 |
10-Q filing | 41.8M shares outstanding |
42M | 130M |
| Aug 07, 2025 |
10-Q filing | 41.8M shares outstanding |
42M | 130M |
| May 13, 2025 |
10-Q filing | 41.8M shares outstanding |
42M | 130M |
| Mar 31, 2025 |
10-K filing | 41.5M shares outstanding |
41M | 130M |
| Nov 07, 2024 |
10-Q filing | 41.8M shares outstanding |
42M | 130M |
| Aug 08, 2024 |
10-Q filing | 41.5M shares outstanding |
42M | 130M |
| May 09, 2024 |
10-Q filing | 40.9M shares outstanding |
41M | 130M |
| Apr 01, 2024 |
10-K filing | 41.5M shares outstanding |
42M | 130M |
| Nov 09, 2023 |
10-Q filing | 40.3M shares outstanding |
40M | 130M |
| Aug 10, 2023 |
10-Q filing | 40.3M shares outstanding |
40M | 130M |
| May 11, 2023 |
10-Q filing | 40.3M shares outstanding |
40M | 130M |
| Apr 17, 2023 |
S-3 filing: Carisma Therapeutics Inc. may offer and sell securities from time to time in one or more offerings of up to $300,000,000 in aggregate offering price. |
200M | 0 |
| Apr 17, 2023 |
S-3 filing: This S-3 filing registers 3,730,608 shares of common stock for resale by selling stockholders of Carisma Therapeutics Inc. |
200M | 0 |
| Mar 08, 2023 |
8-K filing: Carisma sold 1,964,101 shares of common stock at approximately $30.6 million to Carisma Investors prior to the merger, which were later exchanged for shares of the Company's common stock. ($30.6M proceeds) |
200M | 0 |
| Feb 28, 2023 |
10-K filing | 200.5M shares outstanding |
200M | 0 |
| Nov 07, 2022 |
10-Q filing | 200.9M shares outstanding |
200M | 0 |
| Aug 08, 2022 |
10-Q filing | 199.5M shares outstanding |
200M | 0 |
| May 09, 2022 |
10-Q filing | 199.5M shares outstanding |
200M | 0 |
| Feb 28, 2022 |
10-K filing | 182.3M shares outstanding |
180M | 0 |
| Nov 08, 2021 |
10-Q filing | 201.0M shares outstanding |
200M | 0 |
| Aug 09, 2021 |
10-Q filing | 196.0M shares outstanding |
200M | 0 |
| May 10, 2021 |
S-3 filing: This is an S-3 filing for a shelf offering of debt securities, common stock, preferred stock, depository shares, rights and units with a total proposed amount of $200,000,000. It also mentions warrants to purchase common stock. |
170M | 1.3M |
| May 10, 2021 |
10-Q filing | 157.0M shares outstanding |
160M | 12M |
| Mar 15, 2021 |
10-K filing | 167.6M shares outstanding |
170M | 0 |
| Nov 09, 2020 |
10-Q filing | 129.3M shares outstanding |
130M | 0 |
| Aug 10, 2020 |
10-Q filing | 112.6M shares outstanding |
110M | 0 |
| May 11, 2020 |
10-Q filing | 109.8M shares outstanding |
110M | 0 |
| Mar 16, 2020 |
10-K filing | 110.0M shares outstanding |
110M | 0 |